SynCore Biotechnology Co.,Ltd (TPEX:4192)

Market Cap	706.82M -41.4%
Revenue (ttm)	27.04M +15.9%
Net Income	-45.76M
EPS	-1.30
Shares Out	35.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,015
Average Volume	11,417
Open	20.10
Previous Close	20.45
Day's Range	20.10 - 20.10
52-Week Range	19.50 - 32.85
Beta	0.33
RSI	36.18
Earnings Date	May 12, 2026

About TPEX:4192

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 40
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4192

Financial Performance

In 2025, TPEX:4192's revenue was 27.04 million, an increase of 15.88% compared to the previous year's 23.34 million. Losses were -45.76 million, -15.71% less than in 2024.